Shirly Grynberg

Shirly Grynberg

Auto-generated profile, based on publicly available information

Shirly Grynberg

Ella Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
SGShirly Grynberg
Shirly Grynberg
Marilena VeredMarilena Vered
Marilena Vered
RSRonnie Shapira-Frommer
Ronnie Shapira-Frommer
NANethanel Asher
Nethanel Asher
GBGuy Ben-Betzalel
Guy Ben-Betzalel
GCGadi Abebe Campino
Gadi Abebe Campino
Background: Ameloblastoma is a rare odontogenic neoplasm frequently located in the mandible. Standard treatment involves radical bone resection and immediate reconstruction, causing functional, aesthetic, and psychological impairments. The BRAF V600E mutation is present in approximately 80% of mandible ameloblastomas, and BRAF inhibitors have demonstrated sustained responses in unresectable cases. Methods: We identified ameloblastoma patients planned for ablative surgery and screened them for BRAF V600E mutation. Neoadjuvant BRAF inhibitors were offered to facilitate jaw preservation surgery. Retrospective data collection encompassed treatment regimens, tolerability, tumor response, and conversion to mandible preservation surgery. Results: Between 2017 and 2022, a total of 11 patients received dabrafenib (n = 6) or dabrafenib with trametinib (n = 5). The median age was 19 (range = 10-83) years. Median treatment duration was 10 (range = 3-20) months. All (100%) patients achieved a radiological response. Ten (91%) patients successfully converted to mandible preservation surgery with residual tumor enucleation. One patient attained complete radiological response, and surgery was not performed. Among the 10 surgically treated patients, all exhibited a pathological response, with 4 achieving near complete response and 6 partial response. At a median follow-up of 14 (range = 7-37) months after surgery, 1 case of recurrence was observed. Grade 1-2 adverse effects were reported in 8 (73%) patients, with a single case of grade 3 (hepatitis). Dose modification was necessary for 3 patients, and 4 experienced treatment interruptions, while 1 patient permanently discontinued therapy. Conclusions: Neoadjuvant BRAF inhibition may offer a safe and effective strategy for organ preservation in mandible ameloblastoma treatment.

12 December 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
JPJack Pepys
Jack Pepys
RSRonen Stoff
Ronen Stoff
Ramon-Gonen Ramon-GonenRamon-Gonen Ramon-Gonen
Ramon-Gonen Ramon-Gonen
GBGuy Ben-Betzalel
Guy Ben-Betzalel
SGShirly Grynberg
Shirly Grynberg
SSShahar Shelly
Shahar Shelly
Background and objectives: Neurological immune related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune-checkpoints inhibitors (ICI) of all age groups. We investigated the association between age and n-irAEs in patients treated with ICI, and examined the impact of n-irAEs on survival outcomes in a large cohort of melanoma patients. Methods: We conducted a retrospective analysis of advanced melanoma patients treated with ICI at Ella Institute for Immuno-oncology and Melanoma between 1/1/2015 and 20/04/2022. The outcomes of interest were defined as the investigation of age-related frequency and severity of n-irAE, the need for ICI interruption, the treatment required for n-irAE management, the safety of ICI reintroduction, and n-irAE’s impact on survival. Results: ICI was administered to 937 patients. At least one IrAE occurred in 73.5% (n=689) of them. Amongst the study population, 8% (n=76) developed a n-irAE, with a median age of 66 in females and 68 in males at onset. Median follow-up after n-irAE was 1,147 days (IQR: 1091.5 range: 3938). Fewer irAEs occurred in patients older than 70 years (median: 3 events, p=0.04, CI:2.5-4.7), while specifically colitis and pneumonitis were more common in the 18-60 age group (p=0.03 95% CI:0.8,0.38, p=0.009, 95% CI:0.06,0.2). Grade ≥ 3 toxicity was seen in 35.5% of patients across age groups. Median time from ICI administration to n-irAE development was 48 days across age groups. Common n-irAE phenotypes were myositis (44.7%), encephalitis (10.5%), and neuropathy (10.5%). N-irAE required hospitalization in 40% of patients, and steroids treatment in 46% with a median of 4 days from n-irAE diagnosis to steroids treatment initiation. Nine patients needed second-line immunosuppressive treatment. Rechallenge did not cause additional n-irAE in 71% of patients. Developing n-irAE (HR=0.4, 95% CI:0.32,0.77) or any irAE (HR=0.7195% CI:0.56,0.88) were associated with longer survival. Discussion: Neurological-irAEs are a relatively common complication of ICI (8% of our cohort). Older age was not associated with its development or severity, in contrast with non-neurological-irAE which occurred less frequently in the elderly. Rechallenge did not result in life-threatening AEs. Development of any irAE was associated with longer survival, this association was stronger with n-irAE.

7 November 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
RSRonen Stoff
Ronen Stoff
SGShirly Grynberg
Shirly Grynberg
NANethanel Asher
Nethanel Asher
SLShachar Laks
Shachar Laks
YSYael Steinberg
Yael Steinberg
GBGuy Ben-Betzalel
Guy Ben-Betzalel
Introduction: Immunotherapy has revolutionized metastatic Melanoma therapy. The most active regimen is combination therapy of Ipilimumab-Nivolumab (Ipi-Nivo) with response rates (RR) of ~60% and median overall survival (OS) of ~6 years. Immune-related adverse events (irAE) are common (~60% develop grade 3-4) and pose a challenge when treating frail patients. We sought to examine whether Ipi-Nivo therapy is feasible in elderly metastatic melanoma patients.Methods: Electronic records of patients treated at the Ella Lemelbaum Institute with Ipi-Nivo between the years 2017-2021 were screened for age. Elderly patients were defined as age 75 and older (group A) and were matched with records of patients age 75 (median 77) were identified and were matched to 34 younger patients (median age 57). No statistically significant differences were noted in terms of baseline parameters except for BRAF mutation status (group A 15%, group B 47%, p=0.008). Response rate in group A was 38% and is consistent with previously published data. Median PFS was the same for both groups (A = 5.5 months, B= 7.5 months, p=NS). Treatment was similarly tolerated: 35% of group A patients completed 4 cycles of therapy compared to 28% for group B (p=NS). Grade 2-4 irAE were the same (A=58%, B=66%, p=NS) and there was no difference in the need for hospitalization for G3-4 events between the groups. (A=63%, B=69%, p=NS). Further division into 4 age groups (>80 vs 75-79 in group A and 65-74 vs <65 in group B) found no difference in terms of response rate or G3-4 toxicity.Conclusion: Ipilimumab-Nivolumab combination therapy in elderly metastatic Melanoma patients seems to be well tolerated and efficient in selected elderly patients based on performance status and comorbidities, just as in younger patients. This regimen seems to be a feasible treatment option for this age group.

3 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NGNeta Bar-Hai Gochman
Neta Bar-Hai Gochman
GBGuy Ben-Betzalel
Guy Ben-Betzalel
RSRonen Stoff
Ronen Stoff
SGShirly Grynberg
Shirly Grynberg
JSJacob Schachter
Jacob Schachter
NANethanel Asher
Nethanel Asher
Background: Successful treatment with Immune Checkpoint Inhibitors (ICI) requires the balanced activation of the immune system. Over-activation may result in immune-related adverse events (irAEs), which often require steroidal treatment. This study examined the possible impact of steroids on treatment efficacy in melanoma patients concerning initiation timing and dosage. Methods: A retrospective, single-center analysis of patients with advanced melanoma who underwent first-line ICI therapy during 2014–2020 was conducted. Results: Among the 415 patients, two-hundred patients (48.3%) were exposed to steroids during the first line, most of them due to irAEs (n = 169, 84.5%). Nearly a quarter of them were exposed to steroids within the first four weeks of treatment. Surprisingly, steroidal exposure was associated with better progression-free survival (PFS; HR = 0.74, p = 0.015); however, early exposure (within four weeks of treatment) resulted in a significantly shorter PFS compared to late exposure (adjusted HR 3.2, p < 0.001). Conclusions: Early exposure to corticosteroids during the priming phase of ICI therapy could impede the establishment of an effective immune response. These results suggest that caution should be exercised when considering the use of steroids for the management of early-onset irAEs.

24 August 2023 in Life
Verified
Journal Article
Open access
PDF file
NANethanel Asher
Nethanel Asher
CKChristofis Kyprianou
Christofis Kyprianou
ABAviv Barzilai
Aviv Barzilai
RSRonnie Shapira-Frommer
Ronnie Shapira-Frommer
Yaron ShohamYaron Shoham
Yaron Shoham
MHMoti Harats
Moti Harats
An accurate and comprehensive histopathology report is essential for cutaneous melanoma management, providing critical information for accurate staging and risk estimation and determining the optimal surgical approach. In many institutions, a review of melanoma biopsy specimens by expert dermatopathologists is considered a necessary step. This study examined these reviews to determine the critical primary histopathology Breslow score in which a histopathology review would be most beneficial. Histopathology reports of patients referred to our institute between January 2011 and September 2019 were compared with our in-house review conducted by an expert dermatopathologist. The review focused on assessing fundamental histologic and clinical prognostic features. A total of 177 specimens underwent histopathology review. Significant changes in the Breslow index were identified in 103 cases (58.2%). Notably, in many of these cases (73.2%), the revised Breslow was higher than the initially reported score. Consequently, the T-stage was modified in 51 lesions (28.8%). Substantial discordance rates were observed in Tis (57%), T1b (59%), T3a (67%) and T4a (50%) classifications. The revised histopathology reports resulted in alterations to the surgical plan in 15.3% of the cases. These findings emphasize the importance of having all routine pathologies of pigmented lesions referred to a dedicated cancer center and reviewed by an experienced dermatopathologist. This recommendation is particularly crucial in instances where the histopathology review can potentially alter the diagnosis and treatment plan, such as in melanoma in situ and thinner melanomas measuring 0.6–2.2 mm in thickness. Our study highlights the significant impact of histopathology reviews in cutaneous melanoma cases. The observed changes in Breslow scores and subsequent modifications in T-stage classification underline the need for thorough evaluation by an expert dermatopathologist, especially in cases of melanoma in situ and thin melanomas. Incorporating such reviews into routine practice within dedicated cancer centers can improve diagnostic accuracy and guide appropriate treatment decisions, ultimately leading to better patient outcomes.

12 September 2026 in European Journal of Cancer
Verified
Journal Article
Closed access
NANethanel Asher
Nethanel Asher
MAMoti Avner
Moti Avner
NGNadav Goldberg
Nadav Goldberg
GMGal Markel
Gal Markel
NINoa Israei-Weller
Noa Israei-Weller
MLMichal Lotem
Michal Lotem